Mind Medicine (MindMed) Inc. (MNMD)
- Previous Close
8.52 - Open
8.53 - Bid 8.54 x 100
- Ask 8.61 x 100
- Day's Range
8.36 - 8.76 - 52 Week Range
2.41 - 12.22 - Volume
456,716 - Avg. Volume
2,294,272 - Market Cap (intraday)
605.97M - Beta (5Y Monthly) 2.53
- PE Ratio (TTM)
-- - EPS (TTM)
-2.44 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.86
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
www.mindmed.coRecent News: MNMD
Performance Overview: MNMD
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MNMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MNMD
Valuation Measures
Market Cap
600.67M
Enterprise Value
515.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.68
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.84%
Return on Equity (ttm)
-83.59%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-95.73M
Diluted EPS (ttm)
-2.44
Balance Sheet and Cash Flow
Total Cash (mrq)
99.7M
Total Debt/Equity (mrq)
18.08%
Levered Free Cash Flow (ttm)
-25.91M